Evolution of HER2-low expression from primary to recurrent breast cancerFederica Miglietta, Maria Vittoria Dieci, Gaia Griguolo et al.|npj Breast Cancer|2021Cited by 226
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeAleix Prat, Mothaffar F. Rimawi, Tomás Pascual et al.|JNCI Journal of the National Cancer Institute|2019Cited by 168
The immune system and hormone-receptor positive breast cancer: Is it really a dead end?Maria Vittoria Dieci, Valentina Guarneri, Gaia Griguolo et al.|Cancer Treatment Reviews|2016Cited by 128
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatmentFederica Miglietta, Maria Vittoria Dieci, Gaia Griguolo et al.|npj Breast Cancer|2022Cited by 100
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survivalFederica Miglietta, Valentina Guarneri, Michele Bottosso et al.|ESMO Open|2022Cited by 93